ArticlePediatric nephrology (Berlin, Germany)2011
Cyclophosphamide in steroid-dependent nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.Pediatric nephrology (Berlin, Germany) · 2012Trial
- Follow-up Outcomes of 100 Children with Frequently Relapsing and Steroid Dependent Nephrotic Syndrome Treated with Oral Cyclophosphamide: A Retrospective Cohort Study.Indian pediatrics · 2026Article
- The 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European Renal Association Immunonephrology Working Group.Clinical kidney journal · 2026Review
- Article
- Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Predictive factors of long-term disease remission after rituximab administration in patients with childhood-onset complicated steroid-dependent nephrotic syndrome: a single-center retrospective study.Clinical and experimental nephrology · 2023Article
- Long-term obesity prevalence and linear growth in children with idiopathic nephrotic syndrome: is normal growth and weight control possible with steroid-sparing drugs and low-dose steroids for relapses?Pediatric nephrology (Berlin, Germany) · 2022Article
- Oral cyclophosphamide therapy in 100 children with steroid-sensitive nephrotic syndrome: experience from a developing country.Pediatric nephrology (Berlin, Germany) · 2021Observational
- Article
- Treating the idiopathic nephrotic syndrome: are steroids the answer?Pediatric nephrology (Berlin, Germany) · 2019Review
- Positive effects of single-daily high-dose mizoribine therapy after cyclophosphamide in young children with steroid-dependent nephrotic syndrome.Clinical and experimental nephrology · 2019Article
- Predictors of relapse and long-term outcome in children with steroid-dependent nephrotic syndrome after rituximab treatment.Clinical and experimental nephrology · 2017Article
- Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic?Pediatric nephrology (Berlin, Germany) · 2016Article
- Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2016Observational
- Long-term results of children diagnosed with idiopathic nephrotic syndrome; single center experience.Turk pediatri arsivi · 2015Article
- Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2014Article
- Is cyclophosphamide effective in patients with IgM-positive minimal change disease?Pediatric nephrology (Berlin, Germany) · 2012Article
- Chapter 3: Steroid-sensitive nephrotic syndrome in children.Kidney international supplements · 2012Article
- Cyclophosphamide followed by mizoribine as maintenance therapy against refractory steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2011Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In order to determine the long-term effects of cyclophosphamide (CPO) and to identify parameters associated with sustained remission, we retrospectively studied the data from 90 patients with steroid-dependent nephrotic syndrome (SDNS) who received a single course of oral cyclophosphamide (2 mg/kg/day for 10 to 12 weeks). The median follow-up period after CPO was 5.5 years (interquartile range 3.2-8.5). Sustained remission reached the cumulative rate of 57% at 1 year, 42% at 2 years, and 31% at 5 years. For the patients who relapsed, the median threshold dose of prednisone between CPO initiation and first relapse has significantly decreased (22.1 mg/kg/day versus 4.9 mg/kg/day, p < 0.001). No further immunosuppressive agent was required in 60% of all patients. Young age at CPO initiation was associated with a lower rate of sustained remission (p < 0.001). Age at diagnosis of nephrotic syndrome, gender, cumulative dose of CPO (in mg/kg), and level of steroid dependence at CPO initiation did not influence the outcome. The incidence of side effects was low. These findings suggest that despite the wide use of new immunosuppressive agents, a short course of CPO remains an effective second-line therapy in SDNS patients. Optimal efficiency was observed in children over 7.5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.